Terumo Corporation · TSE:4543

Terumo — H1 FY2014 Earnings Presentation

13 slides from Terumo's earnings presentation, Nov 5, 2014

  1. Slide 1: Progress of 1H FY14 and Mid-term Outlook

    Progress of 1H FY14 and Mid-term Outlook Achieve Sustainable and Profitable Growth Terumo Corporation President and Representative Director Yutaro Shintaku November 5, 2014

  2. Slide 2: Roadmap to FY16

    Roadmap to FY16 Secure a foothold in FY13-14 *OPM Target in FY16 Write off assets of certain 20% businesses 17.5% 17% Achieve FY14 guidance FY13 FY14 FY16 Target OPM 20% by FY16 Actual Guidance Target *Excl. amortization of goodwill and intangibles with related to the acquisition of CaridianBCT

  3. Slide 3: Progress in 1H FY14

    Progress in 1H FY14 Continued to write off assets of certain businesses from FY13  Closed the factory for blood bags in Changchun, China (Sep.)  Transform product portfolio of Hospital and Laboratory Business in Europe (Oct.) Made a strong start to achieve FY14 guidance Aim to achieve OPM* 20%

  4. Slide 4: Ongoing Global Industry Consolidation

    Ongoing Global Industry Consolidation FY13 Current 10 20 （$BN） Medtronic 10 20 （$BN） 1 J&J 1 + Covidien 2 Medtronic 2 J&J 3 Baxter 3 Baxter 4 Fresenius BD 4 + CareFusion 5 Covidien 5 Fresenius 6 Abbott 6 Abbott 7 Stryker 7 Stryker 8 BD Zimmer 8 + Biomet 9 Boston 10 B.Braun 9 Boston 11 St. Jude 10 B.

  5. Slide 5: Terumo's Mid-term Outlook

    Terumo’s Mid-term Outlook 1. Continue to launch excellent usability products 2. Expand presence of overseas IS business 3. Launch “Ultimaster” 4. “Double pipeline” to achieve continuous growth 5. Strengthen IS new products R&D in California, U.S. 6. Enter into regenerative and cell therapy market ©

  6. Slide 6: 1. Continue to Launch Excellent Usability Products

    1. Continue to Launch Excellent Usability Products Received FY2014 Good Design Award Misago <Evaluation>  Conformable to vessels flexibly and increased treatment accuracy  Easy to grip Medisafe Finetouch Dispo （Lancet for measuring blood glucose） <Evaluation>  Easy to hold and simple procedure

  7. Slide 7: 2. Expand Presence of Overseas IS Business

    2. Expand Presence of Overseas IS Business EuroPCR 2014 main entrance Exceeding coronary intervention market growth FY06→FY13 CAGR Coronary intervention market +2% Sales Market Terumo overseas IS business +18% ($M) ($M) 1600 12000 Terumo’s booth 1400 Terumo 10000 1200 Coronary intervention market* 8

  8. Slide 8: 3. Launch Ultimaster: Surpass Nobori's Initial Sales Record

    3. Launch Ultimaster: Surpass Nobori’s Initital Sales Record Great contribution in sales and profits (Unit) 2500 2000 1500 Nobori 1000 Ultimaster 500 0 M1 M2 M3 M4 M5 M6 Nobori: launched in Apr, 2008 Ultimaster: launched in May, 2014 © Terumo Corporation 2014/11/5 8/13

  9. Slide 9: 4. "Double Pipeline" to Achieve Continuous Growth

    4. “Double Pipeline” to Achieve Continuous Growth Bioresorbable scaffold Bioresorbable scaffold: Joint development with ART in France 2008 2014 Nobori Ultimaster Hybrid type DES Abluminal coating Thin strut Bioresorbable polymer High comformability to blood vessel © Terumo Corporation 2014/11/5

  10. Slide 10: 5. Strengthen IS new products R&D in California, U.S.

    5. Strengthen IS new products R&D in California, U.S. Full-scale Early Stage Clinical Trial Development Utilize resources Leverage R&D infrastructure Reinforce organization of Silicon Valley of MicroVention of clinical affairs in U.S. Participate in incubation Carotid stent（CASPER） Speedy launch

  11. Slide 11: 6. Enter into Regenerative and Cell Therapy Market

    6. Enter into Regenerative and Cell Therapy Market Cardiac regenerative therapy using cell sheets  Filed an application for the manufacture and sales approval of autologous skeletal myoblast sheets  The first step towards clinical use of the world’s first product to be used as a cardiac regenerat

  12. Slide 12: Terumo BCT Initiatives for Infection Disease

    Terumo BCT Initiatives for Infection Disease  Convalescent Plasma Component collection (Trima and Mirasol) Pathogen Collect plasma and improve reduction safety of blood transfusion technology  Study feasibility to use pathogen reduction technology (Mirasol) to October 22, 2014 inactivate virus fo

  13. Slide 13: IR Contact

    IR Contact Terumo Corporation Corporate Communication (IR) Dept. E-mail: kouhou_terumo01@terumo.co.jp Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i

Terumo — H1 FY2014 Earnings Presentation on 6ix